Physiol. Genomics AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 27: 156-170, 2006. First published August 1, 2006; doi:10.1152/physiolgenomics.00234.2005
1094-8341/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/2/156    most recent
00234.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiekofer, S.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiekofer, S.
Right arrow Articles by Walsh, K.
Received 21 September 2005; accepted in final form 15 July 2006.
Physiological Genomics 27:156-170 (2006)
1094-8341/06 $8.00 © 2006 American Physiological Society

Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure

Stephan Schiekofer, Ichiro Shiojima, Kaori Sato, Gennaro Galasso, Yuichi Oshima and Kenneth Walsh

Molecular Cardiology/Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts

To investigate molecular mechanisms involved in the development of cardiac hypertrophy and heart failure, we developed a tetracycline-regulated transgenic system to conditionally switch a constitutively active form of the Akt1 protein kinase on or off in the adult heart. Short-term activation (2 wk) of Akt1 resulted in completely reversible hypertrophy with maintained contractility. In contrast, chronic Akt1 activation (6 wk) induced extensive cardiac hypertrophy, severe contractile dysfunction, and massive interstitial fibrosis. The focus of this study was to create a transcript expression profile of the heart as it undergoes reversible Akt1-mediated hypertrophy and during the transition from compensated hypertrophy to heart failure. Heart tissue was analyzed before transgene induction, 2 wk after transgene induction, 2 wk of transgene induction followed by 2 days of repression, 6 wk after transgene induction, and 6 wk of transgene induction followed by 2 wk of repression. Acute overexpression of Akt1 (2 wk) leads to changes in the expression of 826 transcripts relative to noninduced hearts, whereas chronic induction (6 wk) led to changes in the expression of 1,611, of which 65% represented transcripts that were regulated during the pathological phase of heart growth. Another set of genes identified was uniquely regulated during heart regression but not growth, indicating that nonoverlapping transcription programs participate in the processes of cardiac hypertrophy and atrophy. These data define the gene regulatory programs downstream of Akt that control heart size and contribute to the transition from compensatory hypertrophy to heart failure.

transgenic mice; cardiac hypertrophy and contractile dysfunction; DNA microarrays; Akt




This article has been cited by other articles:


Home page
CirculationHome page
Y. Oshima, N. Ouchi, K. Sato, Y. Izumiya, D. R. Pimentel, and K. Walsh
Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart
Circulation, June 17, 2008; 117(24): 3099 - 3108.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-Y. Liu, W.-F. Cai, H.-Z. Yang, B. Cui, Z.-R. Chen, H.-Z. Liu, J. Yan, W. Jin, H.-M. Yan, B.-M. Xin, et al.
Bacillus Calmette-Guerin and TLR4 Agonist Prevent Cardiovascular Hypertrophy and Fibrosis by Regulating Immune Microenvironment
J. Immunol., June 1, 2008; 180(11): 7349 - 7357.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. N. Papanicolaou, Y. Izumiya, and K. Walsh
Forkhead Transcription Factors and Cardiovascular Biology
Circ. Res., January 4, 2008; 102(1): 16 - 31.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Z.-Q. Jin, J. Zhang, Y. Huang, H. E. Hoover, D. A. Vessey, and J. S. Karliner
A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury
Cardiovasc Res, October 1, 2007; 76(1): 41 - 50.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Padmasekar, R. Nandigama, M. Wartenberg, K.-D. Schluter, and H. Sauer
The acute phase protein {alpha}2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways*
Cardiovasc Res, July 1, 2007; 75(1): 118 - 128.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
I. Shiojima and K. Walsh
Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway
Genes & Dev., December 15, 2006; 20(24): 3347 - 3365.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.